cilostazol has been researched along with Allergic Encephalomyelitis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kureshiro, J; Kusunoki, S; Miyamoto, K; Tanaka, N | 1 |
| Han, Y; Wang, S; Xu, H; Yan, C; Zhao, X | 1 |
2 other study(ies) available for cilostazol and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Selective phosphodiesterase-3 inhibitor cilostazol ameliorates experimental autoimmune encephalomyelitis.
Topics: Animals; Cilostazol; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Glycoproteins; Intercellular Adhesion Molecule-1; Interferon-gamma; Interleukin-10; Interleukin-17; Lymph Nodes; Mice; Mice, Inbred C57BL; Multiple Sclerosis; Myelin-Oligodendrocyte Glycoprotein; P-Selectin; Peptide Fragments; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Severity of Illness Index; T-Lymphocytes; Tetrazoles; Tumor Necrosis Factor-alpha; Vascular Cell Adhesion Molecule-1 | 2009 |
Suppression of encephalitogenic T-cell responses by cilostazol is associated with upregulation of regulatory T cells.
Topics: Administration, Oral; Animals; Antigens; Cell Differentiation; Cell Proliferation; Cilostazol; Cytokines; Disease Models, Animal; Encephalomyelitis, Autoimmune, Experimental; Female; Mice; Mice, Inbred C57BL; Phosphodiesterase 3 Inhibitors; Phosphodiesterase Inhibitors; Severity of Illness Index; T-Lymphocytes; T-Lymphocytes, Regulatory; Tetrazoles; Th1 Cells; Treatment Outcome | 2010 |